Clinical Trials Logo

Clinical Trial Summary

Neuroborreliosis (NBL) is diagnosed in 10-15% of patients with Lyme borreliosis. In Europe in adults, the main clinical manifestation is called "Bannwarth syndrome". This includes painful meningoradiculitis, sometimes accompanied by cranial nerve neuritis. Current European guidelines issued by the European Federation of Neurological Societies (EFNS) recommend the following triad for the diagnosis of "definite NBL": (i) Neurological symptoms suggestive of NBL without any other obvious cause; (ii) CSF pleocytosis; (iii) Intrathecal production of specific anti-Borreliella antibodies. CXCL13, C-X-C chemokine motif ligand 13, is a chemokine implicated in B cell chemotaxis. Extensive literature exists on the analysis of CXCL13i as a diagnostic marker for acute NBL. A recent meta-analysis from 2018, published by Rupprecht et al finds an overall sensitivity and specificity of 89% and 96% respectively, indicating satisfactory diagnostic value. In this study, the investigators wish to assess the place of this new marker in the diagnosis of neuroborreliosis before proposing it as a test carried out by the Borrelia CNR.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05625100
Study type Observational
Source University Hospital, Strasbourg, France
Contact Benoit JAULHAC, MD, PhD
Phone 33 3 69 55 14 52
Email benoit.jaulhac@chru-strasbourg.fr
Status Recruiting
Phase
Start date July 13, 2020
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05641116 - Effectiveness of an Intervention Combining Adapted Physical Activity and Therapeutic Education in Patients With Chronic Symptoms Attributed to Lyme Borreliosis. N/A
Completed NCT01475708 - Doxycycline in Therapy of Erythema Migrans N/A
Active, not recruiting NCT04801420 - Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population Phase 2
Active, not recruiting NCT00576082 - Borrelia Species in Cutaneous Lyme Borreliosis
Completed NCT03873974 - Performance Evaluation of the DualDur In Vitro Diagnostic System in the Diagnosis of Lyme Borreliosis
Completed NCT03970733 - Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis Phase 2
Completed NCT03769194 - Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study. Phase 2